Real-world use of nirmatrelvir-ritonavir in COVID-19 outpatients during the emergence of Omicron variants BA. 2/BA2. 12.1
NR Aggarwal, KC Molina, LE Beaty, TD Bennett… - Medrxiv, 2022 - medrxiv.org
ABSTRACT Background Ritonavir-boosted Nirmatrelvir (NMV-r), a protease inhibitor with in
vitro activity against SARS-CoV-2, has been shown to reduce risk of progression to severe …
vitro activity against SARS-CoV-2, has been shown to reduce risk of progression to severe …
[HTML][HTML] Real-world use of nirmatrelvir-ritonavir in COVID-19 outpatients during BQ. 1, BQ. 1.1., and XBB. 1.5 predominant omicron variants in three US health systems …
NR Aggarwal, LE Beaty, TD Bennett… - The Lancet Regional …, 2024 - thelancet.com
Summary Background Ritonavir-boosted Nirmatrelvir (NMV-r), a protease inhibitor with in
vitro activity against SARS-CoV-2, can reduce risk of progression to severe COVID-19 …
vitro activity against SARS-CoV-2, can reduce risk of progression to severe COVID-19 …
[HTML][HTML] Real-world use of nirmatrelvir–ritonavir in outpatients with COVID-19 during the era of omicron variants including BA. 4 and BA. 5 in Colorado, USA: a …
NR Aggarwal, KC Molina, LE Beaty… - The Lancet Infectious …, 2023 - thelancet.com
Background Nirmatrelvir is a protease inhibitor with in-vitro activity against SARS-CoV-2,
and ritonavir-boosted nirmatrelvir can reduce the risk of progression to severe COVID-19 …
and ritonavir-boosted nirmatrelvir can reduce the risk of progression to severe COVID-19 …
[HTML][HTML] Nirmatrelvir use and severe Covid-19 outcomes during the Omicron surge
Background The oral protease inhibitor nirmatrelvir has shown substantial efficacy in high-
risk, unvaccinated patients infected with the B. 1.617. 2 (delta) variant of severe acute …
risk, unvaccinated patients infected with the B. 1.617. 2 (delta) variant of severe acute …
Real-world effectiveness of molnupiravir and nirmatrelvir/ritonavir against mortality, hospitalization, and in-hospital outcomes among community-dwelling, ambulatory …
Background Evidence evaluating real-world effectiveness of oral antivirals against Omicron
variants is lacking. Methods An unselected, territory-wide cohort of all initially non …
variants is lacking. Methods An unselected, territory-wide cohort of all initially non …
Real-world effectiveness of nirmatrelvir/ritonavir use for COVID-19: A population-based cohort study in Ontario, Canada
Background Our objective was to evaluate the real world effectiveness of
nirmatrelvir/ritonavir to prevent severe COVID-19 while Omicron and its subvariants …
nirmatrelvir/ritonavir to prevent severe COVID-19 while Omicron and its subvariants …
The effectiveness of novel oral antiviral treatment for non-hospitalized high-risk patients with COVID-19 during predominance of omicron XBB subvariants
Objectives This study investigated the association between nirmatrelvir plus ritonavir (NMV-
r) or molnupiravir and the outcomes of non-hospitalized high-risk patients with COVID-19 …
r) or molnupiravir and the outcomes of non-hospitalized high-risk patients with COVID-19 …
Efficacy of Nirmatrelvir/ritonavir in reducing the risk of severe outcome in patients with SARS-CoV-2 infection: a real-life full-matched case-control study (SAVALO …
I Gentile, A Giaccone, MM Scirocco, F Di Brizzi… - medRxiv, 2024 - medrxiv.org
Introduction Ritonavir-boosted nirmatrelvir (N/r) is an antiviral which targets the main viral
protease, administered to prevent the progression of SARS-CoV-2 infection in patients at …
protease, administered to prevent the progression of SARS-CoV-2 infection in patients at …
Nirmatrelvir or molnupiravir use and severe outcomes from omicron infections
Importance Ritonavir-boosted nirmatrelvir and molnupiravir are currently used in the US and
in other countries to treat nonhospitalized patients who have mild-to-moderate COVID-19 …
in other countries to treat nonhospitalized patients who have mild-to-moderate COVID-19 …
Real-world effectiveness of molnupiravir and nirmatrelvir/ritonavir among COVID-19 inpatients during Hong Kong's Omicron BA. 2 wave: an observational study
Background Real-world evidence on the effectiveness of oral antivirals in mild-to-moderate
COVID-19 patients is urgently needed. This retrospective cohort study aims to evaluate the …
COVID-19 patients is urgently needed. This retrospective cohort study aims to evaluate the …